Navigation Links
Endo Pharmaceuticals Reports First Quarter 2009 Financial Results
Date:4/29/2009

CHADDS FORD, Pa., April 29 /PRNewswire-FirstCall/ -- Endo Pharmaceuticals (Nasdaq: ENDP) today reported financial results for the first quarter of 2009, including results beginning on February 23, 2009 for Indevus Pharmaceuticals, which Endo acquired during the quarter.

Net sales during the first quarter of 2009 increased 16% to $335.3 million compared with $290.3 million in the first quarter of 2008. Net income for the three months ended March 31, 2009 was $39.0 million compared with $59.5 million in the comparable 2008 period. As detailed in the Supplemental Financial Information below, adjusted net income for the three months ended March 31, 2009 was $79.0 million compared with $68.2 million in the same period in 2008.

Diluted earnings per share for the three months ended March 31, 2009 were $0.33 compared with $0.44 in the first quarter of 2008. Adjusted diluted earnings per share for the three months ended March 31, 2009 were $0.67 compared with $0.51 in the same period in 2008.

"We had a solid first quarter during which we diversified our commercial business beyond pain management, reorganized our sales and marketing and R&D groups, and repositioned our company for sustainable future growth," said Dave Holveck, president and chief executive officer of Endo Pharmaceuticals. "I believe our broader therapeutic focus on urology and oncology and more capable specialty infrastructure will enable us to meet aggressive long-term growth targets and adapt quickly to a changing healthcare environment."

Selected Product Review

PAIN PRODUCTS

LIDODERM(R): For the quarter ended March 31, 2009, net sales of LIDODERM decreased 5% to $171.6 million compared with $180.5 million in the same period a year ago. Prescription volume for LIDODERM decrease
'/>"/>

SOURCE Endo Pharmaceuticals
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine news :

1. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
2. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
3. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
4. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
5. Vista Partners Updates Coverage on Tapestry Pharmaceuticals
6. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
7. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Tapestry Pharmaceuticals, Inc.
8. Amylin Pharmaceuticals to Webcast Corporate Overview During 43rd Annual Meeting of the European Association for the Study of Diabetes
9. Major Pharma Clinical Case Studies From Amgen, AstraZeneca, GSK, Intermune, Cephalon Inc, Sunesis Pharmaceuticals and Dartmouth Medical School During Fall Clinical Focused Programs
10. Provectus Pharmaceuticals, Inc. releases summary results of phase 1 metastatic melanoma study
11. Class Settlement Could Result in Considerable Savings for Certain Consumers of Prescription Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... 2013 According to a May 13, 2013 ... of Botox,” Botox injections have become the most ... 2002 (Go to goo.gl/8iYbD). Although it is mostly associated with ... The injection makes facial wrinkles less visible by paralyzing facial ... about three months. This means that people who are conscious ...
(Date:5/21/2013)... 2013 Phoseon Technology will present their ... 20th Annual IMI European Ink Jet Conference (June ... Phoseon continues to invest in product development to enable ... UV LED curing in printing applications. Phoseon currently ... market offering both air cooled and water cooled solutions ...
(Date:5/21/2013)... 2013 MedMar Healing Center announces ... Second Harvest Food Bank. Twenty-eight businesses, including MedMar Healing Center, ... food drive. The goal is to raise food to help ... facing their families in recent years. , “We like ... those in need,” explains Douglas Chloupek of MedMar Healing Center. ...
(Date:5/21/2013)... thrombospondin-1 and prosaposin, play in discouraging cancer metastasis, ... acid fragment of prosaposin that significantly reduces metastatic ... lung cancer. The findings suggest that a prosaposin-based ... of cancers. , The study team, led ... Vivek Mittal, PhD, at Weill Cornell Medical College ...
(Date:5/21/2013)... The Brazilian funding agency for scientific and technological research ... of So Paulo, announced an investment estimated in US$ ... Centers (RIDCs) for a period of up to eleven ... and 7. , Funding for the 17 RIDCs ... funding faculty, technicians, support personnel, and infrastructure). Host institutions ...
Breaking Medicine News(10 mins):Health News:Botox – Is the World’s Most Popular Cosmetic Procedure Safe? 2Health News:San Jose Cannabis Club Helps Feed Hungry Children with Second Harvest Food Bank 2Health News:Changing cancer's environment to halt its spread 2Health News:Changing cancer's environment to halt its spread 3Health News:Research at the cutting edge of knowledge 2
... fix for depression. Even if you are under medical care ... ,The December issue of Mayo Clinic Women's HealthSource offers five ... the risk of recurrence. ,1. Keep active. ... most days has been shown to improve mood. Long-term regular ...
... form of food poison. Then, fame came as a ... the 'miracle poison' and used for an increasing number ... of Mayo Clinic Health Letter covers how this drug ... ,Botulinum toxin blocks communication between nerves and muscles. ...
... drugs causing jaw problems have you wondering: Should you stop ... been reports of partial death of a jawbone (osteonecrosis) related ... to the December issue of Mayo Clinic Health Letter. ... — a disease that causes bones to become brittle and ...
... University of Rochester, Low doses of the drug mifepristone ... //and greatly improves the quality of life in women. ... of the journal, Obstetrics and Gynecology. ,Leiomyoma, ... of all women aged 35 to 49. The non-cancerous ...
... by the Department of Radiology at the University of ... the accuracy of diagnosing meniscal tears. ... there is one MR image with an abnormal finding. ... of 174 patients who had knee MR exams then ...
... one more reason why teenage years are perceived as ... the Pandora's Box has opened. //Such teens are prone ... no'vice' contemporaries, a recent insight indicates. ,The Canadian ... abuse tendencies among 15- to 19-year-olds, drawing on the ...
Cached Medicine News:Health News:Five Self-Care Strategies For Depression 2Health News:Mifepristone Reliable For Treating Uterine Fibroids 2Health News:Mifepristone Reliable For Treating Uterine Fibroids 3
(Date:5/21/2013)... , May 21, 2013 Kepner-Tregoe (KT), ... announced that 13-year veteran Chris Geraghty ... Geraghty,s experience includes more than 20 years serving ... with manufacturing organizations. He succeeds Ray ... as Kepner-Tregoe,s Chairman of the Board and CEO. ...
(Date:5/21/2013)... , May 21, 2013  IsoRay, Inc. (AMEX: ... that it has entered into an exclusive international distribution ... complete product line in Greece . ... seed brachytherapy and medical radioisotope applications for brain cancer, ... gynecologic ("gyn") cancer. IASIS Medical is ...
(Date:5/21/2013)... Inc. (OTC BB: VASO) (the "Company"), a diversified medical technology ... devices and in the domestic sale of diagnostic imaging products, ... President and CEO of Vasomedical, Inc. will present at the ... 2013 in New York City at ... is scheduled to begin at 9:30 a.m. EDT. ...
Breaking Medicine Technology:Kepner-Tregoe, Inc. Promotes Chris Geraghty to Chief Executive Officer 2Kepner-Tregoe, Inc. Promotes Chris Geraghty to Chief Executive Officer 3IsoRay Announces A New International Distributor For Greece 2IsoRay Announces A New International Distributor For Greece 3Vasomedical, Inc. To Present At The Second Annual Marcum LLP MicroCap Conference 2
... Nephros, Inc. (OTC Bulletin Board: NEPH ... products for therapeutic applications, infection control, and water purification, ... reverse split of its common stock will take effect ... 2011. Nephros common stock will be quoted on the ...
... The Florida Society of Pain Management Providers ( www.Flspmp.org ... use in the United States. Until now these statistics ...  Oxycodone dispensed in U.S. 2009 by state (per 100,000 ... FDA.Translation from grams to 15mg tablets for comparison purposes ...
Cached Medicine Technology:Nephros Announces Completion of Reverse Stock Split 2Nephros Announces Completion of Reverse Stock Split 3Nephros Announces Completion of Reverse Stock Split 4Florida Pain Clinic Society: 3.7 Billion Oxycodone Tablets Dispensed in U.S. 2
DePuy 2 Bone Cement is a unique fast-set digital cement that is the excellent choice for small joint procedures such as the patella, glenoid or other extremity joints....
... Palacos® Bone Cement has clinically proven ... cemented arthroplasty. Palacos® is now available ... an antibiotic loaded bone cement cleared ... of a two-stage revision after infection ...
... System for Two-Dimensional Mapping of the ... uniquely merges two sophisticated measurement techniques, ... flowmetry, to a new kind of ... of the retinal micro-circulation., ,Using an ...
... block tear drainage through the canaliculus, synthetic absorbable ... symptoms:, Indicated for use in the treatment ... components of various ocular surface diseases, May be ... related complications and to enhance the retention of ...
Medicine Products: